Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Researchers have found in a new research that among patients with atrial fibrillation who are at moderate-to-high risk for ...

Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.

Patients with a common heart rhythm disorder who took an experimental blood-thinning drug had far fewer bleeding episodes ...

Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral anticoagulant in ...

Lower levels of free factor XI and fewer bleeding events seen in patients with atrial fibrillation at moderate-to-high risk for stroke ...

That's significant because the GI tract is the most common site of bleeding with DOACs, and this type of bleeding is the only ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Atrial fibrillation (AF) is a common heart condition that affects about one in three people at some point in their lives. It ...

A new study highlights that the experimental blood-thinner abelacimab significantly reduces bleeding risks in atrial fibrillation patients compared to standard treatments like rivaroxaban. In trial ...

The median reduction in free factor XI levels was 99% and 97% with abelacimab at a dose of 150mg and 90mg, respectively, at 3 months. (HealthDay News) — Subcutaneous injection of abelacimab ...